High concentration formulation feasibility of human immunoglubulin G for subcutaneous administration

Journal of Pharmaceutical Sciences

Volumn 96, Issue 6, 2007, Pages 1504-1517

  Dani, Bhas ^a,b   Platz, Robert ^a,c   Tzannis, Stelios T ^a  

^a NEKTAR THERAPEUTICS   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c AMGEN INC   (United States)

Author keywords

Circular dichroism; FTIR; High concentration protein delivery; Human immunoglobulin G; Injectables; Monoclonal antibodies; Protein formulation; Spray drying; Stabilization

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; DACLIZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G; INFLIXIMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB;

ARTICLE; ASTHMA; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; CROHN DISEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; FEASIBILITY STUDY; GRAFT REJECTION; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RHEUMATOID ARTHRITIS; SPECTROSCOPY; SPLEEN DISEASE; SPRAY DRYING; STRUCTURE ANALYSIS; UNSTABLE ANGINA PECTORIS; VIRUS INFECTION; VISCOSITY;

EID: 34250728543     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20508     Document Type: Article

References (53)

1. Reuters Business Insight. 2003. The Therapeutic Proteins Outlook To 2007: An analysis of leading products and late-stage pipeline developments. Reuters Business Insight Healthcare. London: MBA Group Limited. pp 94-113.
2. Liu J, Shire SJ. 2002. Reduced viscosity concentrated protein formulations. US Patent Application Number US 2002/0045571.
3. Andya J, Cleland JL, Hsu CC, Lam XM, Overcashier DE, Shire SJ, Yang JYF, Wu SSY. 2001. Protein formulation. US Patent 6,267,958.
4. Platz RM, Patton JS, Foster LC, Eljamal M. 2000. Dispersible antibody compositions and methods for their preparation and use. US Patent 6,165,463.
5. Chan H-K, Clark A, Gonda I, Mumenthaler M, Hsu C. 1997. Spray-dried powders of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm Res 14:431-437.
6. Andya JD, Maa YF, Costantino HR, Nguyen PA, Dasovich N, Sweeney TD, Hsu CC, Shire SJ. 1999. The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody. Pham Res 16:350-358.
7. Codrons V, Vanderbist F, Verbeeck RK, Arras M, Lison D, Preat V, Vanbever R. 2003. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J Pharm Sci 92: 938-950.
8. Patton JS, Foster L, Platz RM. 2004. Methods and compositions for pulmonary delivery of insulin. US Patent 6,685,967.
9. French DL, Edwards DA, Niven RW. 1996. The influence of formulation on emission, deaggregation, and deposition of dry powders for inhalation. J Aerosol Sci 27:769-783.
10. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. 1997. Large porous particles for pulmonary drug delivery. Science 276:1868-1871.
11. Platz RM, Brewer TK, Boardman TD. 2000. Dispersible macromolecule compositions and methods for their preparation and use. US Patent 6,051,256.
12. Elversson J, Millqvist-Fureby A, Alderborn G, Elofsson U. 2003. Droplet and particle size relationship and shell thickness of inhalable lactose particles during spray drying. J Pharm Sci 92:900-910.
13. Kissel T, Brich Z, Bantle S, Lancranjan I, Nimmerfall F, Vit P. 1991. Parenteral depot-systems on the basis of biodegradable polyesters. J Control Release 16:27-42.
14. Burke PA, Klumb LA, Herberger JD, Nguyen XC, Harrell RA, Zordich M. 2004. Poly(lactide-co-glycolide) microsphere formulations of darbepoetin alfa: Spray drying is an alternative to encapsulation by spray-freeze drying. Pharm Res 21:500-506.
15. Nguyen XC, Herberger JD, Burke PA. 2004. Protein powders for encapsulation: A comparison of spray-freeze drying and spray drying of darbepoetin alfa. Pharm Res 21:507-514.
16. Eckhardt BM, Oeswein JQ, Yeung DA, Milby TD, Bewley TA. 1994. A turbidimetric method to determine visual appearance of protein solutions. J Pharm Sci Tech 48:64-70.
17. Tzannis ST, Hrushesky WJM, Wood PA, Przybycien TM. 1997. Adsorption of a formulated protein on a drug delivery device surface. J Coll Interf Sci 189:216-228.
18. Surewicz WK, Mantsch HH. 1988. New insight into protein secondary structure from resolution-enhanced infrared spectra. Biochim Biophys Acta 952:115-130.
19. Holloway PW, Mantsch HH. 1989. Structure of cytochrome b5 in solution by Fourier-transform infrared spectroscopy. Biochemistry 28:931-935.
20. Prestrelski SJ, Arakawa TY, Kenney WC, Byler DM. 1991. The secondary structure of two recombinant human growth factors, platelet-derived growth factor, and basic fibroblast growth factor, as determined by Fourier-transform infrared spectroscopy. Arch Biochem Biophys 285:111-115.
21. Prestrelski SJ, Byler DM, Liebman MN. 1992. Generation of a substructure library for the description and classification of protein secondary structure. II. Application to spectra-structure correlations in Fourier transform infrared spectroscopy. Proteins 14:440-450.
22. Dong A, Huang P, Caughey WS. 1990. Protein secondary structures in water from second-derivative amide I infrared spectra. Biochemistry 29: 3303-3308.
23. Alkner U, Uesson M, Hansson U-B, Glans J. 1982. Circular dichroism of immune complexes with rheumatoid factor activity. Mol Immunol 19:21-25.
24. Broadhead J, Rouan SK, Hau I, Rhodes CT. 1994. The effect of process and formulation variables on the properties of spray-dried β-galactosidase. Pharm Pharmacol 46:458-467.
25. Tzannis ST, Prestrelski SJ. 1999a. Activity-stability considerations of trypsinogen during spray drying: Effects of sucrose. J Pharm Sci 88:351-359.
26. Tzannis ST, Prestrelski SJ. 1999b. Moisture effects on protein-excipient interactions in spray-dried powders. Nature of destabilizing effects of sucrose. J Pharm Sci 88:360-370.
27. Carpenter JF, Crowe JH. 1989. An infrared spectroscopic study of the interactions of carbohydrates with dried proteins. Biochemistry 28:3916-3922.
28. Carpenter JF, Prestrelski SJ, Anchordorguy TJ, Arakawa T. 1994. Interactions of stabilizers with proteins during freezing and drying. In: Cleland JL, Langer R, editors. Formulation and delivery of proteins and peptides, ACS Series Vol. 567. Washington, DC: The American Chemical Society. pp 148-169.
29. Yang J, Cleland JL. 1996. Effect of lyoprotectants on the stability of rhuMAb HER2 formulations, Western Regional Meeting AAPS. South San Francisco, June 1996.
30. Cleland JL, Lam X, Kendrick B, Yang J, Yang T-H, Overcashier D, Brooks D, Hsu C, Carpenter JF. 2001. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J Pharm Sci 90:310-321.
31. Sarciaux J-M, Mansour S, Hageman MJ, Nail SL. 1999. Effects of buffer composition and processing conditions on aggregation of bovine IgG during freeze-drying. J Pharm Sci 88:1354-1361.
32. Hansson U. 1968. Aggregation of human immunoglobulin G upon freezing. Acta Chem Scand 22: 483-489.
33. Paborji M, Pochopin NL, Coppola WP, Bogardus JB. 1994. Chemical and physical stability of chimeric L6: A mouse human monoclonal antibody. Pharm Res 11:764-771.
34. Shire SJ. 2002. Antibody aggregation and its impact on development of high concentration SC formulations, IBC Conference on 'Formulation Strategies for Biopharmaceuticals'. February 2-6, 2002, Miami, FL.
35. Byler DM, Susi H. 1986. Examination of the secondary structure of proteins by deconvolved FTIR spectra. Biopolymers 25:469-487.
36. Arrondo JL, Young NM, Mantsch HH. 1988. The solution structure of concanavalin A probed by FT-IR spectroscopy. Biochim Biophys Acta 952:261-268.
37. Ismail AA, Mantsch HH, Wong PTT. 1992. Aggregation of chymotrypsinogen: Portrait by infrared spectroscopy. Biochim Biophys Acta 1121:183-188.
38. Prestrelski SJ, Byler DM, Liebman MN. 1991. Comparison of various molecular forms of bovine trypsin: Correlation of infrared spectra with X-ray crystal structures. Biochemistry 30:133-143.
39. Boye JI, Ismail AA, Alli I. 1996. Effects of physicochemical factors on the secondary structure of β-lactoglobulin. J Dairy Res 63:97-109.
40. Arrondo JLR, Muga A, Castresana J, Bernabeau C, Goni FM. 1989. An infrared spectroscopic study of β-galactosidase structure in aqueous solutions. FEBS Lett 252:118-120.
41. Amzel LM, Poljak RJ. 1979. Three-dimensional structure of immunoglobulins. Ann Rev Biochem 48:961-977.
42. Goormaghtigh E, Cabiaux V, Ruysschaert JM. 1994. Determination of soluble and membrane protein structure by Fourier transform infrared spectroscopy. III. Secondary structures. In: Hilderson HJ, Ralston GB, editors. Subcellular biochemistry: Physicochemical methods in the study of biomembranes. Vol. 23. New York: Plenum Press. pp 405-450.
43. Cooper EA, Knutson K. 1995. Fourier transform infrared spectroscopy investigations of protein structure. In: Herron JN, editor. Physical methods to characterize pharmaceutical proteins. New York: Plenum Press. pp 101-143.
44. Prestrelski SJ, Tedeschi N, Arakawa T, Carpenter JF. 1993. Dehydration-induced conformational transitions in proteins and their inhibition by stabilizers. Biophys J 65:661-671.
45. Prestrelski SJ, Arakawa T, Carpenter JF. 1994. Structure of proteins in lyophilized formulations using Fourier transform infrared spectroscopy. In: Cleland JL, Langer R, editors. Formulation and delivery of proteins and peptides, ACS Symposium Series. Vol. 567. Washington, DC: The American Chemical Society. pp 148-169.
46. 13C solids NMR. Biopolymers 29:1801-1806.
47. Dong A, Prestrelski SJ, Allison SD, Carpenter JF. 1995. Infrared spectroscopic studies of lyophilization- and temperature-induced protein aggregation. J Pharm Sci 84:415-424.
48. Doi E, Jirgensons B. 1970. Circular dichroism studies on the acid denaturation of γ-Immunoglobulin G and its fragments. Biochemistry 9:1066-1073.
49. McCarthy DA, Drake AF. 1989. Spectroscopic studies on IgG aggregate formation. Mol Immunol 26:875-881.
50. Sirangelo I, Irace G, Bismuto E. 1994. Resolution of the individual tryptophanyl contributions to the near-ultraviolet dichroic activity of apomyoglobin. Photochem Photobiol 59:611-614.
51. Holladay LA, Puett D. 1976. Circular dichroism of corticotropin, fragment 1-24, and model compounds. An assessment of the contributions of the peptide chromophore and aromatic residues. Biopolymers 15:43-59.
52. Robinson JP, Holladay LA, Picklesimer JB, Puett D. 1974. Tetanus toxin conformation. Mol Cell Biochem 5:147-151.
53. Levitt M, Greer J. 1977. Automatic identification of secondary structure in globular proteins. J Mol Biol 114:181-239.